A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries
Purpose
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of SUZ for acute pain after laparoscopic procedures of the intraperitoneal or retroperitoneal cavities or arthroscopic orthopedic procedures.
Condition
- Acute Pain
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m^2) - Scheduled to undergo a procedure that is in one of the following categories that would typically be treated with opioid therapy for at least 72 hours postoperatively such as - Laparoscopic intraperitoneal or retroperitoneal procedure - Arthroscopic orthopedic procedure
Exclusion Criteria
- Participated in previous study with Suzetrigine or received Journavx Other protocol defined Inclusion/Exclusion criteria will apply.
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Suzetrigine (SUZ) |
Participants will receive SUZ for 14 days or until their pain resolves, whichever occurs first. |
|
Recruiting Locations
Memorial Hermann Village
Houston, Texas 77043
Houston, Texas 77043
More Details
- Status
- Recruiting
- Sponsor
- Vertex Pharmaceuticals Incorporated